STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAZE
  4. [Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Maze Therapeutics (MAZE) officer Form 4 details stock sales, option moves

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Maze Therapeutics, Inc. officer Harold Bernstein reported option exercises and share sales. On January 2, 2026, he exercised stock options to acquire 4,432 shares of common stock at $10.42 per share and sold 4,432 shares of common stock at a weighted average price of $40.4304 per share under a Rule 10b5-1 trading plan adopted on September 29, 2025. On January 5, 2026, he exercised options to acquire an additional 412 shares at $10.42 and sold 412 shares at $40.00 per share. Following these transactions, he continued to hold stock options, including 337,563 option shares directly owned, which vest over time according to a set schedule.

Positive

  • None.

Negative

  • None.
Insider Bernstein Harold
Role President, R&D & CMO
Sold 4,844 shs ($196K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 412 $0.00 --
Exercise Common Stock 412 $10.42 $4K
Sale Common Stock 412 $40.00 $16K
Exercise Stock Option (Right to Buy) 4,432 $0.00 --
Exercise Common Stock 4,432 $10.42 $46K
Sale Common Stock 4,432 $40.4304 $179K
Holdings After Transaction: Stock Option (Right to Buy) — 337,563 shares (Direct); Common Stock — 412 shares (Direct)
Footnotes (1)
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.965 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bernstein Harold
(Last) (First) (Middle)
C/O MAZE THERAPEUTICS, INC.
171 OYSTER POINT BOULEVARD, SUITE 300
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President, R&D & CMO
3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/02/2026 M(1) 4,432 A $10.42 4,432 D
Common Stock 01/02/2026 S(1) 4,432 D $40.4304(2) 0 D
Common Stock 01/05/2026 M(1) 412 A $10.42 412 D
Common Stock 01/05/2026 S(1) 412 D $40 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $10.42 01/02/2026 M(1) 4,432 (3) 10/26/2032 Common Stock 4,432 $0 337,975 D
Stock Option (Right to Buy) $10.42 01/05/2026 M(1) 412 (3) 10/26/2032 Common Stock 412 $0 337,563 D
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.965 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
/s/ Courtney Phillips, as attorney-in-fact 01/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Maze Therapeutics (MAZE) officer Harold Bernstein report on this Form 4?

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., reported exercising stock options and selling the resulting common stock in two transactions dated January 2, 2026 and January 5, 2026.

How many Maze Therapeutics shares did Harold Bernstein sell in the reported transactions?

He sold 4,432 shares of common stock on January 2, 2026 at a weighted average price of $40.4304 per share and 412 shares on January 5, 2026 at $40.00 per share.

At what price did Harold Bernstein exercise his Maze Therapeutics stock options?

In both transactions, the reported exercise price for the stock options (Right to Buy) was $10.42 per share.

Is Harold Bernstein’s Form 4 activity under a Rule 10b5-1 trading plan?

Yes. A footnote states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

How many Maze Therapeutics stock options does Harold Bernstein hold after these transactions?

After the reported exercises, he directly beneficially owned 337,563 stock options (Right to Buy), each with a $10.42 exercise price and an expiration date of October 26, 2032.

What is the vesting schedule for Harold Bernstein’s Maze Therapeutics stock options mentioned in the Form 4?

A footnote explains that the option vested as to 1/4 of the total award on October 3, 2023, and thereafter vested or vests as to 1/48 of the total award on each monthly anniversary, subject to his continued service.

What role does Harold Bernstein hold at Maze Therapeutics?

He is reported as an officer of Maze Therapeutics, Inc., with the title President, R&D & CMO, and is not listed as a director or 10% owner.